Experience

AusperBio Secures $63 Million Series B2

September 21, 2025

Cooley advised AusperBio, a privately held, clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B (CHB), on its $63 million Series B2 financing.

Read more

Related contacts

Andrew Harline
Partner in Charge – Singapore, Singapore
Michael Shen
Special Counsel, Shanghai
Lunga Su
Associate, Shanghai
Dr. Madhuri Roy
Partner, Palo Alto
Letian Wei
Legal Consultant, Shanghai

Related Practices & Industries

DualityBio Announces HK$1.64 Billion IPO

April 24, 2025

Cooley advised the underwriters of Duality Biologics (DualityBio), a clinical-stage biotech company focused on the discovery and development of next-generation antibody-drug conjugate therapeutics for patients with cancer and autoimmune diseases, in connection with its HK$1.64 billion global initial public offering (IPO).

Read more

Related contacts

Yiming Liu
Partner in Charge – Shanghai, Shanghai
Michael Yu
Partner in Charge – Hong Kong, Hong Kong
Xander Lee
Partner, Santa Monica
Vince Sampson
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Monica Xu
Special Counsel, Shanghai
Hilda Li
Associate, Hong Kong
Zixiang Liu
Associate, Shanghai
Patrick Sharma
Associate, Santa Monica
Yiying Wang
Counsel, Shanghai
Yunxiang Xu
Associate, Shanghai
Kaiting Yang
Counsel, Hong Kong
Tonny Yu
Associate, Hong Kong
Tonny Yu
Associate, Hong Kong
Letian Wei
Legal Consultant, Shanghai
Cindy Pan
International Legal Project Manager, Hong Kong
Zoe Wang
International Legal Project Manager, Shanghai
Philip Kwan
Senior Legal Assistant, Hong Kong
Jin Wang
Senior Legal Assistant, Beijing

Related Practices & Industries

Hengrui Pharmaceuticals Announces License Agreement With Merck KGaA

April 8, 2025

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck KGaA, Darmstadt, Germany for the commercialization in mainland China of SHR7280, an oral small-molecule gonadotropin-releasing hormone receptor antagonist, for indications including medical-assisted reproduction and gynecology.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Freddy Yip
Associate, Hong Kong
Caroline Vu
Special Counsel, Palo Alto
Letian Wei
Legal Consultant, Shanghai
Marc Suskin
Partner, New York
Sharon Connaughton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Rebecca Ross
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Natasha Leskovsek
Of Counsel, Washington, DC
Jiqiang Lin
Associate, New York
Amanda Pacheco
Associate, Palo Alto

Related Practices & Industries

InnoCare and KeyMed Jointly Announce License Agreement With Prolium

January 20, 2025

Cooley represented Beijing Tiannuo Jiancheng Pharmaceutical Technology, a joint venture of a subsidiary of InnoCare Pharma (HKEX: 09969; SSE: 688428) and a subsidiary of KeyMed Biosciences (HKEX: 02162), in connection with a joint exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02 (CM355), a CD20xCD3 bispecific antibody.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Freddy Yip
Associate, Hong Kong
Michael Shen
Special Counsel, Shanghai
Ivy Wang
Associate, Shanghai
Letian Wei
Legal Consultant, Shanghai
Jameson Davis
Associate, Boston
Robert Eisenbach
Of Counsel, San Francisco
Xander Lee
Partner, Santa Monica
Bin Wang
Special Counsel, Palo Alto
Monica Xu
Special Counsel, Shanghai

Related Practices & Industries

SJ Semiconductor Closes $700 Million Financing

January 2, 2025

Cooley represented SJ Semiconductor (SJSemi), a semiconductor foundry, on the close of a $700 million financing round.

Read more

Related contacts

Ruomu Li
Partner, Shanghai
Letian Wei
Legal Consultant, Shanghai

Related Practices & Industries

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.